Search - tctmd.com

Displaying 421 - 440 of 2035

Sort: Relevancy | Date

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Specialized Stents in STEMI: MGuard From MASTER I to MASTER II

Presenter: Dariusz Dudek, Robert J. de Winter, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Presenter: John A. Bittl, E. Magnus Ohman, James B. Hermiller Jr

October 11, 2015

Presentation TCT 2015

Featured Lecture: New DAPT Duration Recommendations

Presenter: John A. Bittl, E. Magnus Ohman

October 11, 2015

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, Rajesh V Swaminathan

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, Hyeon-Cheol Gwon

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

Presenter: Stephen G. Ellis, John A. Ormiston, Pieter C. Smits

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Presenter: Stephen G. Ellis, John A. Ormiston, Evald H. Christiansen

October 11, 2015

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

Presentation TCT 2015

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Presenter: Stephen G. Ellis, John A. Ormiston, Philip M. Urban

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Presenter: Stephen G. Ellis, John A. Ormiston, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Presenter: Stephen G. Ellis, John A. Ormiston, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Presenter: Stephen G. Ellis, John A. Ormiston, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne

October 11, 2015

Presentation TCT 2015

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston

October 11, 2015

News Opinion Fellow Talk

Researcher Much? A Brief Review of TCT’s Clinical Trial Design and Interpretation Sessions

October 11, 2015

Advertisement

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Specialized Stents in STEMI: MGuard From MASTER I to MASTER II

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Featured Lecture: New DAPT Duration Recommendations

Lessons From the TAXUS Liberté/Prasugrel Substudy

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Biomimetic Stents: Rationale and Current Clinical Results

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Researcher Much? A Brief Review of TCT’s Clinical Trial Design and Interpretation Sessions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content